What you should know about the genomic cancer testing IPO - Guardant Health

Led by former executives from gene-sequencing pioneer Illumina, upcoming IPO Guardant Health (GH) offers the most comprehensive genomic test for non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer. Guardant’s liquid Guardant360 uses samples of patients’ blood to test 73 genes, compared to Thermo-Fisher’s leading tissue-based test Oncomine Dx, which tests 23 genes.

Here are three other things you should know about Guardant....

To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.